| CASE REPORT |
|
| Year : 2013 | Volume
: 8
| Issue : 3 | Page : 250-252 |
Unusual cause of hyperammonemia in two cases with short-term and long-term valproate therapy successfully treated by single dose carglumic acid
Çigdem Seher Kasapkara1, Murat Kangin2, Funda Feryal Tas2, Yasemin Topçu3, Remezan Demir2, Mehmet Nuri Özbek4
1 Department of Pediatric Metabolism and Nutrition, Diyarbakir Children's Hospital, Diyarbakir, Turkey
2 Department of Pediatrics, Diyarbakir Children's Hospital, Diyarbakir, Turkey
3 Department of Pediatric Neurology, Diyarbakir Children's Hospital, Diyarbakir, Turkey
4 Department of Pediatric Endocrinology, Diyarbakir Children's Hospital, Diyarbakir, Turkey
Correspondence Address:
Çigdem Seher Kasapkara
Department of Pediatric Metabolism and Nutrition, Diyarbakir Children's Hospital, Diyarbakir
Turkey
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1817-1745.123697
Valproic acid (VPA) is an antiepileptic drug which is used in the treatment of various seizure disorders including tonic-clonic, myoclonic, absence, partial seizures and psychiatric disorders. VPA is usually well tolerated, but severe adverse effects may occur. Hyperammonaemic encephalopathy (HE) is a rare and potentially fatal complication of VPA treatment. The mechanism by which valproate induces hyperammonemia remains incompletely understood but is likely to relate to the urea cycle. Herein we present two cases with valproate-induced hyperammonemia at therapeutic valproate levels without signs of liver failure and were successfully treated by a single dose of carglumic acid.
[FULL TEXT] [PDF]*
|
